Minerva Neurosciences (NERV) Financials

Minerva Neurosciences (NASDAQ: NERV) remains a pre-revenue biotech with a very large cash burn and a highly unusual balance sheet profile. Across the last several quarters, the company has continued to report zero revenue, persistent operating losses, and meaningful swings in cash that appear tied to financing activity and non-operating items rather than core business performance.

What stands out most: Q1 2026 showed a dramatic deterioration in reported earnings, with a net loss of $125.4 million versus a much smaller loss in the prior quarter and prior-year periods. That quarter also included a very large negative “other income / expense” line, which heavily distorted the bottom line.

• Cash and short-term investments totaled about $78.2 million at the end of Q1 2026, giving Minerva near-term liquidity despite ongoing losses.
• The company generated $1.6 million of interest and investment income in Q1 2026, helping offset a portion of operating losses.
• Operating cash burn was relatively modest in Q1 2026 compared with the reported net loss, with net cash used in operations of $5.4 million.
• Research and development spending has fallen sharply over the past year, suggesting the company may be operating on a more restrained development budget than in 2024.
• The balance sheet still carries goodwill of $14.9 million and a large noncurrent liability of $338.6 million, which makes the equity structure look complex and somewhat opaque.
• Minerva continues to report no product revenue, so results remain dependent on financing, investment income, and pipeline progress rather than commercial sales.
• Q1 2026 posted a net loss of $125.4 million, a sharp worsening from the roughly $2.7 million loss in Q3 2025 and a much larger loss than the prior-year quarters.
• The quarter included a massive other income / expense loss of $109.4 million, which drove most of the headline deterioration.
• Despite the cash balance, the company still burned $45.3 million in investing activities in Q1 2026, mainly from purchases of investments.
• Shareholders’ equity remains negative at about $(254.0) million, underscoring the company’s fragile financial position.

Trend over the last four years: Minerva has consistently operated at a loss, with quarterly operating expenses typically in the $2.8 million to $7.2 million range before the Q1 2026 jump. The company briefly posted a large accounting profit in Q3 2024, but that appears to have been driven by non-operating gains rather than recurring business performance. Since then, the pattern has reverted to recurring losses and cash consumption.

Balance sheet trend: Cash has generally declined from the high $40 million area in 2023 to $32.7 million in Q1 2026, though short-term investments helped push total liquid resources higher in the latest quarter. Even so, the company’s negative equity and large long-term liability base suggest that liquidity should be monitored closely.

Bottom line: NERV remains a speculative biotech story. The company has enough cash and investments to keep operating for now, but the absence of revenue, continuing losses, and volatile non-operating items make the stock highly dependent on future clinical or financing developments.